-
Innovation Ranking
NewInnovation Ranking – GeoVax Labs Inc
GeoVax Labs Inc (GeoVax) is a biotechnology company that develops immunotherapies and vaccines against cancers and various infectious diseases. GeoVax develops vaccines using its novel patented Modified Vaccinia Ankara-Virus like Particle (MVA-VLP) vector vaccine platform focused on therapy areas such as infectious diseases like HIV, Lassa fever, Ebola, Zika virus, malaria, Hepatitis B, coronavirus, and cancers related to solid tumors and HPV-associated head and neck cancer. It has partnerships for preclinical and clinical testing with various government, academic and corporate...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gedeptin in Recurrent Head And Neck Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gedeptin in Recurrent Head And Neck Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gedeptin in Recurrent Head And Neck Squamous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gedeptin in Salivary Gland Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gedeptin in Salivary Gland Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gedeptin in Salivary Gland Cancer Drug Details: Gedeptin (Ad/PNP-F-araAMP) is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Gedeptin in Nasopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gedeptin in Nasopharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gedeptin in Nasopharyngeal Cancer Drug Details: Gedeptin (Ad/PNP-F-araAMP) is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SNC-102 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SNC-102 in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SNC-102 in Relapsed Multiple Myeloma Drug Details: SNC-102 is under development...
-
Product Insights
Human Papillomavirus Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Human Papillomavirus Infections - Drugs In Development, 2023’, provides an overview of the Human Papillomavirus Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Human Papillomavirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Zika Virus Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Zika Virus Infections - Drugs In Development, 2023’, provides an overview of the Zika Virus Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Zika Virus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Salivary Gland Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Salivary Gland Cancer - Drugs In Development, 2023’, provides an overview of the Salivary Gland Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Salivary Gland Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Marburgvirus Infections (Marburg Hemorrhagic Fever) – Drugs In Development, 2023
Global Markets Direct’s, ‘Marburgvirus Infections (Marburg Hemorrhagic Fever) - Drugs In Development, 2023’, provides an overview of the Marburgvirus Infections (Marburg Hemorrhagic Fever) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Marburgvirus Infections (Marburg Hemorrhagic Fever), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Nasopharyngeal Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Nasopharyngeal Cancer - Drugs In Development, 2023’, provides an overview of the Nasopharyngeal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Nasopharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...